Biomarker Study in Patients With Herpes Zoster

NCT ID: NCT05685797

Last Updated: 2025-09-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-25
• Study Completion Date: 2023-11-30

Brief Summary

Investigators performed this study to investigate the expression levels inflammatory cytokine and neurotransmitters (calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin) in peripheral blood of participants with herpes zoster.

Detailed Description

Sudden and electrick shooting sensation of face is an important clinical feature of herpes zoster. The severe and excruciating nature of pain intensity associated with herpes zoster can impair the physical and psychosocial well-being of the patient, however, pathophysiologic mechanism of herpes zoster still remains unclear.

Recentrly, there have been a few studies suggesting biomarker levels in the blood and CSF level, however, further study is required to elucidate the action mechanism.

Up to 90% of patients can achieve pain reduction using medical therapy alone. However, 10% -15% of herpes zoster cases demonstrate a minimal response to medication with various side effects. Radiofrequency thermocoagulation (RFT) of the trigeminal ganglion is an alternative treatment option for patients who are poor candidates for microvascular decompression or show serious side effects to medication. Recent study revealed that RFT of the trigeminal ganglion resulted in Barrow Neurological Institute (BNI) pain scale I or II in 71.7% of patients, with a median time to recurrence of 36 months.

Although patients experience significant pain relief after RFT, it is uncertain whether inflammatory cytokine and neurocytokine (CGRP, substance P, VIP) are reduced.

Conditions

Herper Zoster

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

herpes zoster (acute) patients with intervention

Patients with herpes zoster receiving 2 times of nerve block

Group Type: EXPERIMENTAL

Herpes zoszter (acute)with inter vention

Intervention Type: PROCEDURE

nerve block

patients with chronic herpes zoster receiving 2 times of nerve block

Patients with herpes zoster receiving 2 times of nerve block

Group Type: EXPERIMENTAL

Herpes zoszter (acute)with inter vention

Intervention Type: PROCEDURE

nerve block

Interventions

Herpes zoszter (acute)with inter vention

nerve block

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• patients with NRS more than 4
• patients who failed medical treatment
• patients showing severe adverse reaction with medication

Exclusion Criteria

• Patients showing allergic reaction to local anesthetics
• Patients with coagulation abnormality

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Keimyung University Dongsan Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Ji Hee Hong

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Hong ji HEE

Daegu, , South Korea

Countries

South Korea

Other Identifiers

2022-09-016

Identifier Type: -

Identifier Source: org_study_id